Federal Circuit Reverses Ruling Invalidating Patent Claims

The Case Behind the Headline

The ruling grew out of litigation between REGENXBIO and the Trustees of the University of Pennsylvania, on one side, and Sarepta Therapeutics on the other. The patent at issue, U.S. Patent No. 10,526,617, involves cultured host cells containing a recombinant nucleic acid molecule. In the lawsuit, REGENXBIO alleged that Sarepta’s Duchenne muscular dystrophy gene-therapy product used the accused technology in a way that infringed the patent.

The business stakes were anything but theoretical. Sarepta’s Elevidys became a closely watched gene-therapy product in the Duchenne muscular dystrophy market, and the commercial significance of the platform made the patent fight far more than an academic debate about molecular biology and statutory interpretation. When a patent linked to a major therapy survives or dies, licensing value, bargaining power, investor confidence, and competitive strategy all move with it.

Back in January 2024, the district court granted summary judgment for Sarepta and held the asserted claims ineligible under 35 U.S.C. § 101. The lower court reasoned that the claims effectively covered naturally occurring subject matter and leaned on familiar Supreme Court cases such as Funk Brothers, Myriad, and the broader Alice/Mayo framework. In other words, the claims were treated less like a patentable engineered composition and more like a dressed-up natural phenomenon.

Why the District Court Invalidated the Claims

The district court’s basic instinct was simple: if the building blocks come from nature, maybe the finished invention is still too natural to patent. It viewed the claimed components as naturally occurring sequences and concluded that combining those sequences in a host cell did not transform the invention into patent-eligible subject matter. The court also concluded that the claims lacked an inventive concept at step two of the eligibility analysis.

One of the lower court’s most important moves was its analogy to Funk Brothers, the old Supreme Court case involving mixed bacterial cultures. That case has long haunted life-sciences patent disputes because it stands for the idea that merely packaging natural things together, without changing their essential character, does not magically create a patentable invention. The district court essentially saw the REGENXBIO claims as a modern molecular version of that old problem.

That may have sounded neat on paper, but the Federal Circuit thought it missed the science and the law. And frankly, that is where this case gets interesting. The appellate court did not just say, “We disagree.” It said the analogy itself was flawed because the claimed host cells were not mere repackaged natural products. They were engineered constructs containing recombinant material that does not arise in nature on its own.

Why the Federal Circuit Reversed

1. The Claims Had to Be Viewed as a Whole

The Federal Circuit emphasized a point patent litigators repeat so often it should probably be printed on courthouse coffee mugs: claims must be evaluated as a whole. Sarepta urged the court to isolate the naturally occurring AAV sequence and treat the rest of the claim language as conventional window dressing. The Federal Circuit refused. A claim does not become legally invisible just because some of its pieces are known in the art.

This part of the decision is bigger than the biotech context. It pushes back on a recurring litigation habit in patent cases: reduce the invention to a stripped-down abstraction, then declare victory. The appellate court reminded everyone that Section 101 is not supposed to erase real claim limitations just because they complicate the invalidity argument.

2. Human Engineering Matters

The panel also focused on what the inventors actually created. The claimed host cells contained recombinant nucleic acid molecules assembled through human intervention, including material from different species. That matters because the resulting composition was not something nature simply hands over if you hike through the woods with a pipette and enough optimism.

According to the Federal Circuit, the claimed cells were “markedly different” from anything occurring in nature. That phrase is crucial in eligibility law. If an invention reflects human engineering that creates a materially different composition, especially one that does not and cannot exist in nature on its own, the patent-eligibility analysis shifts in a major way. The court concluded that this case looked far more like Chakrabarty than Funk Brothers.

3. Utility Still Counts

The Federal Circuit also pointed to the practical utility of the claimed compositions. The patent specification described benefits for gene delivery and gene therapy. The lower court had discounted that point because the claims were not drafted around a specific therapeutic use. The appellate court took a more realistic view. A human-made biological construct does not lose its significance merely because the claim is framed as a composition rather than a treatment method.

That is an important nuance. Patent law does not require every valid composition claim to read like a full instruction manual for the commercial product. If the claimed subject matter is structurally different from natural material and has meaningful utility, that can strongly support eligibility.

4. Section 101 Is Not the Same as Sections 102 and 103

Maybe the most practical takeaway is the Federal Circuit’s warning not to conflate eligibility with novelty or obviousness. A patent challenger may still argue that a claim is anticipated or obvious. But that is a different inquiry. The appellate court essentially told parties and tribunals: stop trying to smuggle novelty arguments into Section 101 wearing a fake mustache.

That line should resonate with companies across industries. When courts use Section 101 as a catch-all shortcut, they risk skipping the more disciplined analysis required by the rest of the Patent Act. The reversal makes clear that a claim is not automatically ineligible simply because a challenger can describe some elements as conventional or naturally derived.

Why This Matters for Patent Owners, Challengers, and the Market

For patent owners, the decision is a meaningful boost, especially in life sciences. It suggests that carefully drafted claims directed to engineered cells, recombinant constructs, and other laboratory-made compositions still have a strong path through Section 101 when the invention is genuinely human-made and materially different from what exists in nature.

For accused infringers, the ruling is a caution sign. A quick eligibility knockout may not work when the claims recite specific structural features and the science shows real transformation. Companies defending high-stakes product lines may need to lean harder on noninfringement, written description, enablement, anticipation, obviousness, or claim-construction arguments instead of expecting Section 101 to do all the heavy lifting.

For investors, deal teams, and licensing professionals, the message is equally practical. An appellate reversal like this can materially change the value of a portfolio overnight. A patent family that looked mortally wounded at the district-court level can suddenly become a live negotiating asset again. That can affect royalty discussions, freedom-to-operate assessments, collaboration strategy, and even how companies talk to Wall Street about competitive risk.

Specific Example: Why the Stakes Were So High

This dispute did not arise in a vacuum. Sarepta’s Elevidys became the first FDA-approved gene therapy for certain Duchenne muscular dystrophy patients in 2023, and the FDA expanded the approval in 2024. By early 2026, Sarepta reported roughly $898.7 million in full-year 2025 Elevidys revenue. So when the Federal Circuit revived the patent claims, it revived a fight tied to a product with major clinical, commercial, and strategic importance.

That is why this ruling attracted so much attention in patent and biotech circles. It was not just about molecular phrasing in a claim chart. It was about how courts should treat innovation in gene therapy, where inventions often involve naturally derived biological materials that have been transformed through sophisticated laboratory engineering. If those inventions are too quickly labeled “natural,” the patent system becomes a shaky place to build next-generation therapeutics.

What the Reversal Does Not Mean

Now for the legal fine print nobody should ignore: a reversal on Section 101 does not mean REGENXBIO automatically wins the case. The Federal Circuit did not award infringement damages, bless every claim challenge, or guarantee a final victory on remand. It simply held that these asserted claims should not have been invalidated as patent-ineligible subject matter at this stage.

That distinction matters. Patent cases are marathon events disguised as bursts of drama. After an eligibility reversal, the parties still may fight over claim construction, infringement, invalidity under other statutes, damages, willfulness, licensing history, expert testimony, and settlement. So yes, this was a big win for the patent owner. No, it was not the finish line.

A Broader Trend: The Federal Circuit Is Pushing Back on Oversimplification

The REGENXBIO decision also fits a broader pattern. In more than one recent patent-eligibility case, the Federal Circuit has shown frustration with analyses that reduce concrete inventions to vague concepts or isolate only the “natural” or “abstract” part of the claim. A notable example is PowerBlock v. iFit, where the court reversed a Section 101 ruling against claims involving automated dumbbell technology. Different field, same message: do not oversimplify the invention until it barely resembles what was actually claimed.

That trend should matter to patent prosecutors and litigators alike. Drafting strategy now has even more reason to emphasize structural detail, human intervention, physical configuration, technological improvement, and real-world utility. Meanwhile, litigators challenging patents should be careful not to build a Section 101 argument that sounds elegant but ignores half the claim language. Appellate courts have started to notice that habit, and they do not seem charmed by it.

Experience From the Real World: What These Reversals Feel Like in Practice

Anyone who has worked around patent litigation knows that a Federal Circuit reversal lands like a thunderclap. For patent owners, the experience is often a mix of relief, vindication, and immediate new stress. Relief, because claims that looked dead are suddenly alive again. Vindication, because the appellate court has effectively said the invention was oversimplified or misunderstood. And new stress, because the case is now back in motion, which means more experts, more budgets, more strategy meetings, and more late-night emails that begin with the terrifying phrase, “Following up on the remand.”

For in-house counsel, these reversals often confirm something they suspected from the start: the hardest part of a Section 101 fight is not always the law, but the framing. If the other side can convince a judge to describe an engineered invention in the most generic way possible, even a sophisticated technology can start to look suspiciously ordinary. That is why experienced patent teams spend so much time on language, analogies, scientific declarations, and teaching the court what the invention actually is. In cases like REGENXBIO, that effort can make the difference between “natural phenomenon” and “human-made composition.” Those are not just legal labels. They can change the value of a case by hundreds of millions of dollars.

For accused infringers, the experience is different but just as intense. A district-court invalidity ruling can feel like an early escape hatch. When the Federal Circuit closes that hatch, defense strategy has to evolve fast. Teams that were leaning heavily on eligibility must pivot to deeper noninfringement theories, prior-art attacks, damages containment, and sometimes settlement planning. Nobody loves discovering that the quick win was only on loan.

Biotech companies feel these reversals in a particularly personal way because their patents are often tied to years of research, regulatory risk, manufacturing complexity, and enormous capital burn. When a court says a lab-engineered platform is “too natural,” scientists hear something different from lawyers: they hear that years of manipulation, testing, optimization, and design are being collapsed into a shrug. That is one reason the REGENXBIO reversal resonated so strongly. It acknowledged that combining sequences from different sources and transforming host cells is not the same thing as tossing ingredients into a legal salad bowl and calling it invention.

Perhaps the most practical experience-based lesson is this: appellate reversals do not erase uncertainty, but they do restore negotiating power. Once claims are revived, licensing conversations change. Investors ask different questions. Competitors update risk models. Boards pay closer attention. And trial teams go from postmortem mode back to war-room mode. In the patent world, that is not a small emotional swing. It is a full-contact pivot.

Conclusion

The Federal Circuit’s reversal in REGENXBIO v. Sarepta is a powerful reminder that courts should not flatten complex inventions into simplistic categories. The appellate court did not announce a free-for-all for biotech patents, and it did not end the long-running Section 101 debate. What it did do is reinforce a basic but crucial principle: when patent claims describe a human-made, materially different composition, courts must analyze the invention that was actually claimed, not a stripped-down caricature of it.

For patent owners, that is encouraging. For challengers, it is a warning. And for anyone watching the future of biotech, gene therapy, and patent litigation, it is one of the clearest recent signals that the Federal Circuit is willing to reverse rulings invalidating patent claims when lower courts push Section 101 too far.

SEO Tags